ArticleEuropean journal of nuclear medicine and molecular imaging2025
Divergent prognostic utility of metabolic risk scores in large B-cell lymphoma subtypes: a real-world analysis.
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLarge B-cell lymphomas (LBCL) include diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), and subtypes such as transformed non-Hodgkin's lymphoma (tNHL), primary mediastinal B-cell lymphoma (PMBL), and double/triple-hit lymphomas (DHL/THL). While metabolic risk scores based on metabolic tumor volume (MTV) have demonstrated prognostic value in DLBCL, NOS, their applicability to other LBCL subtypes remains unclear.
methodsBaseline [
resultsWe included tNHL (n = 88), DHL/THL (n = 32), PMBL (n = 26) and others (n = 49), and compared them to a cohort of previously published DLBCL, NOS (n = 355). IMPI demonstrated the highest C-index amongst the metabolic risk scores in tNHL for progression-free survival (PFS), overall survival, time to progression and progression of disease within 12 months, but was outperformed by the IPI. For DHL/THL the highest C-indices were observed for MTV/WHO PS. For PMBL the clinical PET score showed the highest C-indices. SDmax improved prognostic predictions in PMBL and tNHL, but not in DHL/THL. Multivariate analysis identified independent predictors of PFS in tNHL, including IPI and SUV
conclusionMetabolic risk scores show variable prognostic value across LBCL subtypes. Subtype-specific metabolic models may enhance personalized risk stratification and guide treatment approaches.
Indexed as
Identifiers
40518458What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.